|
Elan Stock Price ELNCompany Description : A neuroscience-based biotechnology company that is focused on discovering, developing, manufacturing and marketing advanced therapies in neurology, autoimmune diseases, and severe pain. url: www.elan.com |
| | Change (p) | Change (%) | Cur | Bid | Ask | High | Low | Open | Volume | Time | A | |  | -0.11 | -1.70 | 6.35 | 5.74 | 6.44 | 6.53 | 6.31 | 6.51 | 2632976 | 20:00:00 | | |
| stock Prices on this screen are 15 minutes delayed |  Register for free Elan stock prices. |
Johnson & Johnson and Elan Corporation plc Announce Closing of Transaction Related to Alzheimer's Immunotherapy Program and Equi : NEW BRUNSWICK, N.J. and DUBLIN, Sept. 17 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE:JNJ) and Elan Corporation plc (NYSE:ELN) today announced that JANSSEN Alzheimer Immunotherapy, a newly formed subsidiary of Johnson...
Free Elan Stock ChartsElan Historical Stock Chart
 | | Elan Monthly Stock Chart
 | Elan Intraday stock chart
 | Register for FREE streaming stock charts featuring overlays, annotations and more than 80 different studies including Level 2 Scope and Average True Range. Get the Latest Elan stock Price, quotes, trades and FREE Elan stock charts, company information, annual reports, market news and announcements from ADVFN. We offer Intraday and historical stock prices for Elan (ELN) and other New York Stock Exchange listed companies as well as company financials, Level 2 Data and the latest investor information from our stock market Message Boards. | | Elan News & Message Board Discussion
| Latest Elan News Headlines | | Date | Time | Source | | | 09/17/2009 | 9:00AM | PRNUS | Johnson & Johnson and Elan Corporation plc Announce Closing of Transaction Related to Alzheimer's Immunotherapy Program and Equi |
| 08/03/2009 | 8:09AM | PRNUS | Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia |
| 07/31/2009 | 5:18PM | PRNUS | FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia |
| 07/14/2009 | 9:00AM | PRNUS | Studies Presented at International Conference on Alzheimer's Disease Reveal Substantial Economic Costs and Caregiver Burden Asso |
| 07/02/2009 | 7:57AM | PRNUS | Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimer's Immunotherapy Program and Equity Invest |
| 02/06/2009 | 10:37AM | PRNUS | Seven Summits Research Releases Comments on BAC, FCX, CRM, DKS, and ELN |
| 01/13/2009 | 10:26AM | PRNUS | Seven Summits Research Releases Comments on BAC, WLP, ELN, LXK, and MAC |
| 01/07/2009 | 6:50AM | PRNUS | Intellect Neurosciences, Inc. Grants to Top Tier Global Pharmaceutical Company License to Certain Alzheimer's Patents and Patent |
| 12/19/2008 | 8:04AM | PRNUS | AstraZeneca and MAP Pharmaceuticals Announce Worldwide Collaboration to Develop and Commercialize Unit Dose Budesonide |
| 12/18/2008 | 8:00AM | PRNUS | Jazz Pharmaceuticals Announces Issuance of Key Patent for Once-A-Day LUVOX CR(R) |
| 12/12/2008 | 5:45PM | DJN | PRESS RELEASE: Major Shareholder Jack W. Schuler Calls for Termination of Elan CEO |
| 12/11/2008 | 4:38PM | PRNUS | Shareholder Class Action Filed Against Elan Corporation, plc by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP |
|
|
Elan Company Information| Sector | Turnover (m) | Profit (m) | EPS - Basic | PE ratio | Mkt Cap (m) | NMS | | | 0.00 | 0.00 | | | 0.0 | N/A |
| Register for FREE access to the latest Elan company information and fundamental data for other USA Equity companies. More than 100 separate statistics including accounts payable / sales and inventory / sales. |
Latest Elan Stock Trade| Type | Size | Price | Date | Tr.Time | Units | | | 550 | 6.35 | 11/23/2009 | 5:04PM | USD |
|
|
| |